Market revenue in 2024 | USD 43.3 million |
Market revenue in 2030 | USD 69.3 million |
Growth rate | 8.2% (CAGR from 2025 to 2030) |
Largest segment | Cephalosporin |
Fastest growing segment | Glycopeptide |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cephalosporin, Aminoglycosides, Glycopeptide, Other Drug Class |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sepsis therapeutics market will help companies and investors design strategic landscapes.
Cephalosporin was the largest segment with a revenue share of 65.36% in 2024. Horizon Databook has segmented the Australia sepsis therapeutics market based on cephalosporin, aminoglycosides, glycopeptide, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia sepsis therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Australia sepsis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account